A systematic review reported that, of 13 studies evaluating changes in body weight (including 633 patients receiving bDMARDs), 8 (including 558 patients) reported significant weight gain from baseline (mean: 1.63 kg); 2 (including 24 patients) reported a nonsignificant trend toward weight gain with treatment, and 3 (including 51 patients) showed no change in body weight.
← all excerpts
Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis.
1
—
—